Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study

Dig Liver Dis. 2020 Nov;52(11):1323-1330. doi: 10.1016/j.dld.2020.08.034. Epub 2020 Sep 20.

Abstract

Background: There are few data concerning patients with Crohn's disease (CD) complicated by a stricture of the upper gastrointestinal tract (UGT).

Aims: We evaluated the outcome and management of CD patients complicated by a stricture of the UGT.

Methods: We performed a retrospective multicenter study including all CD patients with a non-passable symptomatic UGT stricture on endoscopy. Primary outcome measure was surgery-free survival from diagnosis of stricture. Efficacy of medical, endoscopic, and surgical treatments, and identification of predictors of surgery were also evaluated.

Results: 60 CD patients with an UGT stricture were included. 60% of the strictures were located in the duodenum. With a median follow-up of 5.5 (IQR: 3.0-12.0) years since stricture diagnosis, surgical-free survival was 75% and 64% at 1 and 5 years, respectively. At the end of the follow up, 27 (45%) patients underwent surgery. 77 endoscopic procedures were performed in 30 patients with an immediate success of 81% and a clinical benefit in 84% of the procedures. In multivariate analysis, anti-TNF treatment initiation was associated with a reduced risk of surgery.

Conclusion: CD UGT strictures are mainly located in the duodenum. Medical and endoscopic treatments allow to avoid surgery in half of the patients.

Keywords: Crohn's disease; Endoscopic treatment; Stricture; Surgery; Upper gastrointestinal tract.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Belgium
  • Constriction, Pathologic / etiology*
  • Constriction, Pathologic / therapy
  • Crohn Disease / complications
  • Crohn Disease / therapy*
  • Endoscopy, Gastrointestinal / standards
  • Female
  • France
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Retrospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Upper Gastrointestinal Tract / pathology*
  • Young Adult

Substances

  • Tumor Necrosis Factor Inhibitors